Comparative Renoprotective Effect of Febuxostat and Allopurinol in Predialysis Stage 5 Chronic Kidney Disease Patients: A Nationwide Database Analysis
Sign Up to like & getrecommendations! Published in 2019 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.1697
Abstract: Hyperuricemia has been associated with chronic kidney disease (CKD) progression. The antihyperuricemic febuxostat's potential renoprotective effect has been demonstrated in stage 1–3 CKD. Large‐scale studies comparing the renoprotective potential of febuxostat and allopurinol in advanced… read more here.
Keywords: predialysis stage; febuxostat; stage; febuxostat allopurinol ... See more keywords
Evaluation of Febuxostat Initiation During an Acute Gout Attack: A Prospective, Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2020 at "Joint bone spine"
DOI: 10.1016/j.jbspin.2020.03.017
Abstract: OBJECTIVE Urate-lowering treatment (ULT) is recommended in gout management. However, initiation of ULT during an acute gout flare is still inconclusive. This study aimed to evaluate the efficacy and safety of the ULT febuxostat administered… read more here.
Keywords: gout attack; febuxostat; acute gout; initiation ... See more keywords
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial
Sign Up to like & getrecommendations! Published in 2020 at "The Lancet"
DOI: 10.1016/s0140-6736(20)32234-0
Abstract: BACKGROUND Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat… read more here.
Keywords: allopurinol; patients gout; non; febuxostat ... See more keywords
Febuxostat for the treatment of hyperuricaemia in gout
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2018.1498842
Abstract: ABSTRACT Introduction: Febuxostat is a potent non-purine selective xanthine oxidase inhibitor approved by the FDA in 2009 for management of hyperuricemia in people with gout. Areas covered: The authors summarize the pre-clinical studies and pivotal… read more here.
Keywords: gout; febuxostat; treatment hyperuricaemia; hyperuricaemia gout ... See more keywords
FP278The Inhibition of Xanthine Oxidoreductase by Febuxostat Ameliorates Oxidative Stress in Contrast Induced Nephropathy through the AMPK-NOXs-HIF-1α Signaling in Mice
Sign Up to like & getrecommendations! Published in 2019 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfz106.fp278
Abstract: Type : Oral Abstract Submission No. : OR-1280 The Inhibition of Xanthine Oxidoreductase by Febuxostat Ameliorates Oxidative Stress in Contrast Induced Nephropathy through the AMPK-NOXsHIF-1α Signaling in Mice Yu Ah Hong, Keum Jin Yang, Jung… read more here.
Keywords: nephrology; ampk; febuxostat; inhibition ... See more keywords
Febuxostat protects HAVECs from ox-LDL-induced injury and monocyte attachment.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of cardiovascular pharmacology"
DOI: 10.1097/fjc.0000000000001326
Abstract: ABSTRACT Atherosclerosis (AS) is a common cardiovascular disease with high morbidity and mortality. The pathogenesis of AS is closely related to endothelial dysfunction, which is mainly induced by oxidative stress, inflammation, and enhanced adhesion of… read more here.
Keywords: induced injury; injury monocyte; febuxostat; ldl ... See more keywords
Advances in Urate-Lowering Therapy: Time to Revisit High-Dose Febuxostat.
Sign Up to like & getrecommendations! Published in 2017 at "American journal of therapeutics"
DOI: 10.1097/mjt.0000000000000565
Abstract: Successful gout treatment depends almost entirely on lowering serum urate levels.1 Over the last decade, the Food and Drug Administration (FDA) approved 3 new urate-lowering medications: febuxostat, pegloticase, and lesinurad (joining the long-ago-approved drugs allopurinol… read more here.
Keywords: uric acid; febuxostat; trial; drug ... See more keywords
Confounding by indication and ethnicity difference? Comment on ‘Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data’
Sign Up to like & getrecommendations! Published in 2020 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2020-218056
Abstract: We read with great interest the study by Singh and Cleveland1 that investigated the risk of hypersensitivity reactions (HRs) with allopurinol and febuxostat using Medicare claims data. These authors analysed a national cohort in the… read more here.
Keywords: febuxostat; medicare claims; using medicare; claims data ... See more keywords
Formulation and Characterization of Nanosized Ethosomal Formulations of Antigout Model Drug (Febuxostat) Prepared by Cold Method: In Vitro/Ex Vivo and In Vivo Assessment
Sign Up to like & getrecommendations! Published in 2019 at "AAPS PharmSciTech"
DOI: 10.1208/s12249-019-1556-z
Abstract: Febuxostat (FXT) is a xanthine oxidase (XO) drug which indicated for the treatment of gout. FXT loaded nanosized ethosomes were prepared using cold method with varied concentrations of ethyl alcohol and soya lecithin (SL). The… read more here.
Keywords: febuxostat; vivo; study; drug ... See more keywords
Febuxostat Improves Insulin Resistance in the Skeletal Muscle In Vitro and In Vivo
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes"
DOI: 10.2337/db18-1927-p
Abstract: Hyperuricemia is closely associated with various metabolic disorders such as diabetes, hypertension, dyslipidemia, and cardiovascular diseases. Xanthine oxidoreductase (XOR) is a key enzyme known to catalyze purines to uric acid. Febuxostat is an orally-active, potent,… read more here.
Keywords: skeletal muscle; febuxostat; ltd; effect ... See more keywords
Combination of Panax ginseng C. A. Mey and Febuxostat Boasted Cardioprotective Effects Against Doxorubicin-Induced Acute Cardiotoxicity in Rats
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2022.905828
Abstract: Doxorubicin (DOX) is an anticancer agent for treating solid and soft tissue malignancies. However, the clinical use of DOX is restricted by cumulative, dose-dependent cardiotoxicity. Therefore, the present study aimed to assess the cardioprotective effects… read more here.
Keywords: dox; cardioprotective effects; combination; febuxostat ... See more keywords